BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $DNLI readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06602193-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~BIIB122 225 mg readout (P2) · Denali Therapeutics Inc. $DNLI
DESCRIPTION:Safety and Pharmacodynamic Effects of BIIB122 in Participants W
 ith LRRK2-Associated Parkinson's Disease (LRRK2-PD)\n\nPrimary completion 
 date: 2027-03 (estimated) — month only\, shown on the 1st\nOriginally pl
 anned: 2026-04-30 (+10.0 months)\nPhase 2 · Neuro · Parkinson Disease\nE
 nrollment: 50 · Sites: 20\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://datacutoff.com/radar.html?nct=NCT06602193\nhttps://clinicaltrials.
 gov/study/NCT06602193
URL:https://datacutoff.com/radar.html?nct=NCT06602193
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06075537-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~tividenofusp alfa readout (P2/3) · Denali Therapeutics Inc. $DNLI
DESCRIPTION:An Extension Study of the Long-Term Safety\, Tolerability\, and
  Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysacch
 aridosis Type II (MPS II) From Study DNLI-E-…\n\nPrimary completion date
 : 2027-06 (estimated) — month only\, shown on the 1st\nPhase 2/3 · Rare
  · Mucopolysaccharidosis II\nEnrollment: 99 · Sites: 31\n\nPrimary compl
 etion = last participant's primary-endpoint data collected\; topline resul
 ts usually follow weeks to months later. Sponsor-reported\, often an estim
 ate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06
 075537\nhttps://clinicaltrials.gov/study/NCT06075537
URL:https://datacutoff.com/radar.html?nct=NCT06075537
CATEGORIES:Rare,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
